Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature

BACKGROUND: The risk of severe cardiovascular toxicity, specifically thromboembolic events (TE), in patients with cervical cancer receiving concurrent irradiation and cisplatin chemotherapy is reported to be less than 1% in several large prospective trials. However, the anecdotal risk appears to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Anders, Jon C, Grigsby, Perry W, Singh, Anurag K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526743/
https://www.ncbi.nlm.nih.gov/pubmed/16722547
http://dx.doi.org/10.1186/1748-717X-1-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526743/
https://www.ncbi.nlm.nih.gov/pubmed/16722547
http://dx.doi.org/10.1186/1748-717X-1-14

Ejemplares similares